Ceri Medical, a specialist epidemiological development services company designing, running and reporting epidemiological and observational studies, has been acquired by Business & Decision Life Sciences. Headquartered in Paris, France, Ceri Medical specializes in providing strategic consulting and operational support for non-interventional studies.
According to the company, in the last full year the turnover of Ceri Medical was over $2.1 million and many of France’s large pharmaceutical companies are active clients.
Xavier Gobert, chief strategy officer, Business & Decision Life Sciences, said, “Business & Decision Life Sciences’ CRO is helping our customers reduce the time and cost of drug development. We are achieving this through the combination of our industry expertise and enabling innovative technologies. With the increasing focus on cost/benefit analyses by government agencies and institutional payers, Ceri Medical’s epidemiological capabilities will further differentiate and enhance our services to help our worldwide customers better understand the burden and causes of health problems in human populations. Additionally, Ceri Medical’s well-established presence in France also will broaden our existing capabilities in this important market.”
“Our expertise in running non-interventional studies now has the support platform of a well-respected, biometrics specialist CRO that, through its approach to study conduct, will allow our clients to benefit through greater cost savings,” said Serge Bergal, CEO of Ceri Medical.
With the integration of the two companies, Ceri Medical's management will become part of senior leadership team of the expanded BDLS organization.